In the first nine months of 2008, the company reported profit of 16.9 million lei and turnover of 155.4 million lei.

In 2009, the turnover increased slightly to 157.7 million lei (€37.3 million), while revenues fell 3.7% to 161.4 million lei (€38.2 million).

Expenses dropped 3.6% to 142.2 million lei (€33.7 million) compared to Jan-Sep period 2009.

In August, the drug maker said it would export products worth $2 million in US, after receiving license from the Food and Drug Administration.

The company has a share capital of 45.49 million lei, divided into 454.9 million shares at a face value of 0.10 lei.

The majority shareholder of the drug maker is the Ministry of Health with 53.01% interest, while FIC Oltenia holds 10.10%. Hyposwiss fund’s equity is below 5%, according to latest reports.

The company’s market cap is 304.7million lei (€70.9 million), according to yesterday’s closing quote of 0.67 lei/share.